

## DAFTAR PUSTAKA

1. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. *Int J Antimicrob Agents*. 2020;55(5).
2. Coronavirus disease (COVID-19) [Internet]. [cited 2021 Mei 16]. [Internet]. Available from: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19>
3. Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). *Diabetes Metab Syndr Clin Res Rev* [Internet]. 2020;14(3):251–4. Available from: <https://doi.org/10.1016/j.dsx.2020.03.012>
4. Guan, Wei-Jie; Ni, Zheng-Yi; Hu, Yu; Liang, Wen-Hua; Ou, Chun-Quan; He, Jian-Xing; Liu, Lei; Shan, Hong; Lei, Chun-Liang; Hui, David S C; Du, Bin; Li, Lan-Juan; Zeng, Guang; Yuen, Kwok-Yung; Chen, Ru-Chong; Tang, Chun-Li; Wang, Tao; Chen, Ping-Yan; Xiang, Jie; Li, Shi-Yue; Wang, Jin-Lin; Liang, Zi-Jing; Peng, Yi-Xiang; Wei, Li; Liu, Yong; Hu, Ya-Hua; Peng, Peng; Wang, Jian-Ming; Liu, Ji-Yang; Chen, Zhong; Li, Gang; Zheng, Zhi-Jian; Qiu, Shao-Qin; Luo, Jie; Ye, Chang-Jiang; Zhu, Shao-Yong; Zhong, Nan-Shan. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382(18):1708–20.
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* [Internet]. 2020;395(10229):1054–62. Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3)
6. Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S., Huang, H., Zhang, L., Zhou, X., Du, C., Zhang, Y., Song, J., Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, X., Chen, D., Xiong, W., Xu, L., Song, Y. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180(7):934–43.
7. Satria RMA, Tutupoho RV, Chalidyanto D. Analisis Faktor Risiko Kematian dengan Penyakit Komorbid Covid-19. *J Keperawatan Silampari*. 2020;4(1):48–55.
8. Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., Merson, L., Lee, J., Plotkin, D., Sigfrid, L., Halpin, S., Jackson, C., Gamble, C., Horby, P. W., Nguyen-Van-Tam, J. S., Ho, A., ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC

- WHO Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ*. 2020;369(March):1–12.
9. Stefani Agustin Parapasan RA. Tatalaksana Pasien Covid-19 Dengan Komorbid Diabetes Mellitus. *J Penelit Perawat Prof* [Internet]. 2020;1(November):89–94. Available from: <http://jurnal.globalhealthsciencegroup.com/index.php/JPPP/article/download/83/65>
  10. N, Lestari., B I. Diabetes Melitus Sebagai Faktor Risikokeparahan Dan Kematian Pasien covid-19: Meta-Analisis. *Biomedika* [Internet]. 2021;13(1):83–94. Available from: <https://journals.ums.ac.id/index.php/biomedika/article/view/13544/6527>
  11. Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. *PLoS One* [Internet]. 2021;16(4 April):1–11. Available from: <http://dx.doi.org/10.1371/journal.pone.0250147>
  12. Lu H. Drug treatment options for the 2019-new coronavirus (2019- nCoV). *Biosci Trends*. 2020;14(1):69–71.
  13. Drożdżal S, Rosik J, Lechowicz K, Machaj F, Kotfis K, Ghavami S, Łos MJ. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. *Drug Resist Updat* [Internet]. 2020;53(April):100719. Available from: <https://doi.org/10.1016/j.drug.2020.100719>
  14. Nabila, Putri Bakri studi literatur obat-obat potensial dalam pengobatan coronavirus disease 2019 (COVID-19). Diploma thesis, Universitas Andalas. 2020.
  15. Parasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. *Postgrad Med J*. 2021;97(1147):312–20.
  16. Esakandari H, Nabi-afjadi M, Fakkari-afjadi J, Farahmandian N, Miresmaeili S, Bahreini E. A comprehensive review of COVID-19 characteristics. *Biol Proced Online*. 2020;2:1–10.
  17. Akpınar EE. Pathogenesis of COVID-19. *urasian J Pulmonol Publ by Wolters Kluwer - Medknow*. 2020;3–5.
  18. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. *Nat Rev Microbiol* [Internet]. 2021;19(3):141–54. Available from: <http://dx.doi.org/10.1038/s41579-020-00459-7>
  19. Attaway AH, Scheraga RG, Bhimraj A, Biehl M, Hatipoğ Lu U. Severe covid-19 pneumonia: Pathogenesis and clinical management. *BMJ*. 2021;372.
  20. Beranda | Satgas Penanganan COVID-19 [Internet]. [cited 2021 Sept 27]. [Internet]. Available from: [Covid19.go.id](https://www.covid19.go.id)
  21. Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: Mechanisms underlying disease severity and progression. *Physiology*. 2020;35(5):288–301.

22. Leap J, Villgran V, Cheema T. COVID-19: Epidemiology, Pathophysiology, Transmission, Symptoms. *Crit Care Nurs Q*. 2020;43(4):338–42.
23. National Institutes of Health. Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19). Nih [Internet]. 2021;2019. Available from: <https://www.covid19treatmentguidelines.nih.gov/>
24. Burhan E, Susanto AD, Nasution SA, Eka G, Pitoyo ceva W, Susilo A, Firdaus I, Santoso A, Juzar DA, Arif SK. Pedoman tatalaksana COVID-19 edisi 4. 2022. 79–85 p.
25. IDF. IDF Diabetes Atlas 9th edition 2019. In International Diabetes Federation Diabetes Atlas, Ninth Edition. 2019.
26. Joseph T. DiPiro, Gary C. Yee, Michael Posey, Stuart T. Haines, Thomas D. Nolin VE. *Pharmacotherapy: A Pathophysiologic Approach*. 12rd Edition. McGraw-Hill Education; 2020.
27. American Association of Diabetes. ADA standards of diabetes care 2021. Vol. 44, *Diabetes Care*. 2021. p. S21–226.
28. Perkeni. Pedoman Pengelolaan dan Pencegahan DM Tipe 2 Dewasa Indonesia. *Perkumpulan Endokrinol Indones* [Internet]. 2019;113. Available from: <https://pbperkeni.or.id/wp-content/uploads/2020/07/Pedoman-Pengelolaan-DM-Tipe-2-Dewasa-di-Indonesia-eBook-PDF-1.pdf>
29. Decroli E. *Buku Diabetes Melitus Tipe 2*. Padang: Fakultas Kedokteran Unand; 2019.
30. Kun'ain UIA, Rahardjo SS, Tamtomo DG. Meta-Analysis: The Effect of Diabetes Mellitus Comorbidity on the Risk of Death in Covid-19 Patients. *Indones J Med*. 2020;5(4):368–77.
31. Zhu, L., She, Z. G., Cheng, X., Qin, J. J., Zhang, X. J., Cai, J., Lei, F., Wang, H., Xie, J., Wang, W., Li, H., Zhang, P., Song, X., Chen, X., Xiang, M., Zhang, C., Bai, L., Xiang, D., Chen, M. M., Liu, Y., Li, H. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. *Cell Metab* [Internet]. 2020;31(6):1068-1077.e3. Available from: <https://doi.org/10.1016/j.cmet.2020.04.021>
32. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. *Nat Rev Endocrinol* [Internet]. 2021;17(1):11–30. Available from: <http://dx.doi.org/10.1038/s41574-020-00435-4>
33. Bornstein, S. R., Rubino, F., Khunti, K., Mingrone, G., Hopkins, D., Birkenfeld, A. L., Boehm, B., Amiel, S., Holt, R. I., Skyler, J. S., DeVries, J. H., Renard, E., Eckel, R. H., Zimmet, P., Alberti, K. G., Vidal, J., Geloneze, B., Chan, J. C., Ji, L., & Ludwig, B. Practical recommendations for the management of diabetes in patients with COVID-19. *Lancet Diabetes Endocrinol* [Internet]. 2020;8(6):546–50. Available from: [http://dx.doi.org/10.1016/S2213-8587\(20\)30152-2](http://dx.doi.org/10.1016/S2213-8587(20)30152-2)
34. Varghese E, Mathews S, Id S, Liskova A, Id PK, Bu D. Diabetes and coronavirus ( SARS-CoV-2 ): Molecular mechanism of M AU etformin



- intervention and the scientific basis of drug repurposing. 2021;2:1–20.
35. Maturoh, Imas., Anggita NT. *Metodologi Penelitian Kesehatan*. 2018.
  36. Daniel WW, Cross CL. *BIostatistics. A Foundation for Analysis in the Health Sciences*. 10th ed. John Wiley & Sons. New York; 2019.
  37. Al-Salameh A, Lanoix JP, Bennis Y, Andrejak C, Brochot E, Deschasse G, Dupont H, Goeb V, Jaureguy M, Lion S, Maizel J, Moyet J, Vaysse B, Desailoud R, Ganry O, Schmit JL, Lalau JD. Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes. *Diabetes Metab Res Rev*. 2021;37(3).
  38. Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): A systematic review and meta-analysis. *BMJ Open*. 2020;10(10):1–10.
  39. Luo H, Liu S, Wang Y, Phillips-Howard PA, Ju S, Yang Y, Wang D. Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: A retrospective, multicentre cohort study. *BMJ Open*. 2020;10(10).
  40. Wang Y, Lu X, Li Y, Chen H, Chen T, Su N, Huang F, Zhou J, Zhang B, Yan F, Wang J. Clinical course and outcomes of 344 intensive care patients with COVID-19. *Am J Respir Crit Care Med*. 2020;201(11):1430–4.
  41. Kusumawardani LA, Maria N, Fanani YN. Potential drug interactions analysis of COVID-19 patients at a hospital in West Java Analisis potensi interaksi obat pada pasien rawat inap COVID-19 pada suatu rumah sakit di Jawa Barat adanya reaksi efek samping yang tidak diinginkan . Pada bulan Juli 20. 2021;17(2).
  42. Arief I, Sumarny R, Sumiyati Y, Kusuma I. Hubungan Karakteristik Klinik dan Profil Pengobatan dengan Parameter Hematologi dan Lama Rawat Pasien Covid-19 Di Rumah Sakit Yarsi Jakarta. *Syntax Lit ; J Ilm Indones [Internet]*. 2021;6(11):5693–706. Available from: <https://www.jurnal.syntaxliterate.co.id/index.php/syntax-literate/article/view/4556/2611%0Ahttps://www.jurnal.syntaxliterate.co.id/index.php/syntax-literate/article/view/4556>
  43. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 1 April 2020. Pedoman Tatalaksana COVID-19. 2020. 50 p.
  44. Badan Pengawas Obat dan Makanan. *INFORMATORIUM OBAT COVID-19 DI INDONESIA Edisi 3*. Badan POM. 2021. 1–8 p.
  45. PDPI, PERKI, PAPDI, PERDATIN, IDAI. Pedoman tatalaksana COVID-19 Edisi 3 Desember 2020 [Internet]. Pedoman Tatalaksana COVID-19. 2020. 36–37 p. Available from: <https://www.papdi.or.id/download/983-pedoman-tatalaksana-covid-19-edisi-3-desember-2020>
  46. Lukito JI. Tinjauan Antivirus untuk Terapi COVID-19. 340 Cdk-286. 2020;47(5):PP:342.
  47. Marliana L, Marliani L. Analisis Perbandingan Lama Rawat Inap Pasien Terdiagnosis Covid-19 Antara Pemberian Terapi Oseltamivir Dengan

- Favipiravir di RSUD R.Syamsudin S.H Sukabumi Periode Mei s.d Juli 2021. *J Sos Sains*. 2021;1(11):1413–22.
48. Voinsky I, Baristaite G, Gurwitz D. Effects of age and sex on recovery from COVID-19: Analysis of 5769 Israeli patients. *J Infect*. 2020;81:102–3.
  49. Baihaqi FA, Rumaropen H. Faktor-Faktor yang Berhubungan dengan Lama Rawat Inap Pasien COVID-19 di RSUD Serui Provinsi Papua: Studi Potong Lintang. *J Penyakit Dalam Indones*. 2022;8(4):187.
  50. Raghavan A, Nanditha A, Satheesh K, Susairaj P, Vinita R, Chandrasekaran S, Palaniappan T, Thillai Vallal S, Subair Khan A, Snehalatha C, Ramachandran A. Profile and prognosis of patients hospitalized for COVID-19 virus infection with and without diabetes – An observational study from South India. *Diabetes Metab Syndr Clin Res Rev* [Internet]. 2021;15(4):102143. Available from: <https://doi.org/10.1016/j.dsx.2021.05.016>
  51. Nafakhi H, Alareedh M, Al-Buthabhak K, Shaghee F, Nafakhi A, Kasim S. Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq. *Diabetes Metab Syndr Clin Res Rev* [Internet]. 2021;15(1):33–8. Available from: <https://doi.org/10.1016/j.dsx.2020.12.014>
  52. Thiruvengadam G, Lakshmi M, Ramanujam R. A Study of Factors Affecting the Length of Hospital Stay of COVID-19 Patients by Cox-Proportional Hazard Model in a South Indian Tertiary Care Hospital. *J Prim Care Community Heal*. 2021;12.
  53. Fujifilm announces the Start of a New Phase III Clinical Trial of Anti-influenza Drug Avigan® Tablet in Japan, Targeting COVID-19 Patients [Internet]. Available from: <https://www.fujifilm.com/jp/en/news/hq/6478>
  54. vashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., Lomakin, N. V., Merkulova, E. A., Papazova, N. A., Pavlikova, E. P., Savchuk, N. P., Simakina, E. N., Sitdekov, T. A., Smolyarchuk, E. A., Tikhomolova, E. G., Yakubova, E. V., ... Ivachtchenko, A. V. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. *Clin Infect Dis*. 2021;73(3):531–4.
  55. Bosaeed, M., Alharbi, A., Mahmoud, E., Alrehily, S., Bahlaq, M., Gaifer, Z., Alturkistani, H., Alhagan, K., Alshahrani, S., Tolbah, A., Musattat, A., Alanazi, M., Jaha, R., Sultana, K., Alqahtani, H., Al Aamer, K., Jaser, S., Alsaedy, A., Ahmad, A., Abalkhail, M., ... Alaskar, A. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. 2020;(January).
  56. Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, Soliman S, Elbahnasawy M, Badawi R, Tageldin MA. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. *Arch Virol* [Internet]. 2021;166(3):949–54. Available from:

<https://doi.org/10.1007/s00705-021-04956-9>

57. Stoian AP, Catrinoiu D, Rizzo M, Ceriello A. Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. *Diabetes Metab Res Rev*. 2020;
58. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., Lopez de Castilla, D., Finberg, R. W., Dierberg, K., Tapson, V., Hsieh, L., Patterson, T. F., Paredes, R., Sweeney, D. A., Short, W. R., Touloumi, G., ... ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19 — Final Report. *N Engl J Med*. 2020;383(19):1813–26.
59. Garibaldi BT, Wang K, Robinson ML, Zeger SL, Bandeen-Roche K, Wang MC, Alexander GC, Gupta A, Bollinger R, Xu Y. Comparison of Time to Clinical Improvement with vs without Remdesivir Treatment in Hospitalized Patients with COVID-19. *JAMA Netw Open*. 2021;4(3):1–14.
60. Maloberti, A., Ughi, N., Bernasconi, D. P., Rebora, P., Cartella, I., Grasso, E., Lenoci, D., Del Gaudio, F., Algeri, M., Scarpellini, S., Perna, E., Verde, A., Santolamazza, C., Vicari, F., Frigerio, M., Alberti, A., Valsecchi, M. G., Rossetti, C., Epis, O. M., Giannattasio, C., ... On The Behalf Of The Niguarda Covid-Working Group. Heart rate in patients with sars-cov-2 infection: Prevalence of high values at discharge and relationship with disease severity. *J Clin Med*. 2021;10(23):1–11.
61. Vital Sign Assessment [Internet]. [cited 2022 March 2]. [Internet]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK331/>
62. Bagi HM, Soleimanpour M, Abdollahi F, Soleimanpour H. Evaluation of clinical outcomes of patients with mild symptoms of coronavirus disease 2019 (COVID-19) discharged from the emergency department. *PLoS One* [Internet]. 2021;16(10 October):1–11. Available from: <http://dx.doi.org/10.1371/journal.pone.0258697>
63. Brunetti ND, Poliseno M, Bottalico IF, Centola A, Montemurro L, Sica S, Santantonio T, Lo Caputo S. Safety and heart rate changes in Covid-19 patients treated with Remdesivir. *Int J Infect Dis* [Internet]. 2021;112:254–7. Available from: <https://doi.org/10.1016/j.ijid.2021.09.036>
64. Sarotama A, Melyana. Implementasi Peringatan Abnormalitas Tanda-Tanda Vital pada Telemedicine Workstation. *J Nas Sains dan Teknol* [Internet]. 2019;21(1):1–9. Available from: <https://jurnal.umj.ac.id/index.php/semnastek/article/view/5236>
65. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19 [Internet]. 2020. Available from: <https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.3319?src=getftr>
66. Geneva II, Cuzzo B, Fazili T, Javaid W. Normal body temperature: A systematic review. *Open Forum Infect Dis*. 2019;6(4):1–7.
67. Fauzar F, Kurniati R, Abdullah F, Kam A. The Profile of COVID-19 Patients in Semen Padang Hospital Indonesia. *J Kesehat Andalas*. 2021;10(1):45.



68. Shinkai, M., Tsushima, K., Tanaka, S., Hagiwara, E., Tarumoto, N., Kawada, I., Hirai, Y., Fujiwara, S., Komase, Y., Saraya, T., Koh, H., Kagiya, N., Shimada, M., Kanou, D., Antoku, S., Uchida, Y., Tokue, Y., Takamori, M., Gon, Y., Ie, K., ... Iwata, S. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. *Infect Dis Ther [Internet]*. 2021;10(4):2489–509. Available from: <https://doi.org/10.1007/s40121-021-00517-4>
69. Mejía F, Medina C, Cornejo E, Morello E, Vásquez S, Alave J, Schwalb A, Málaga G. Oxygen saturation as a predictor of mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru. *PLoS One*. 2020;15(12 December):1–12.
70. Fata UH, Febriana L. Oxygen Saturation (SPO2) in Covid-19 Patients. *J Ners dan Kebidanan (Journal Ners Midwifery)*. 2021;8(3):290–4.
71. Minuljo TT, Prima Y, Anindita C, Nugroho H, Seno H, Gde T, Pemayun D, Achsan M, Sofro U. Karakteristik dan Keluaran Pasien COVID-19 dengan DM di RS Umum Pusat Dr . Kariadi. *Medica Hosp*. 2020;7(1A):150–8.
72. Solaymani-dodaran M, Ghanei M, Bagheri M, Qazvini A, Hosseini-shokouh S, Shahrokhi M, Yassin Z, Javad M, Asghari A, Namazi M, Ziaie S. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. *Int Immunopharmacol*. 2021;95(January):1–8.
73. Izzi-Engbeaya, C., Distaso, W., Amin, A., Yang, W., Idowu, O., Kenkre, J. S., Shah, R. J., Woin, E., Shi, C., Alavi, N., Bedri, H., Brady, N., Blackburn, S., Leczycka, M., Patel, S., Sokol, E., Toke-Bjolgerud, E., Qayum, A., Abdel-Malek, M., Hope, D., Salem, V. Adverse outcomes in COVID-19 and diabetes: A retrospective cohort study from three London teaching hospitals. *BMJ Open Diabetes Res Care*. 2021;9(1).
74. Erickson TB, Chai PR, Boyer EW. Chloroquine, hydroxychloroquine and COVID-19. *Toxicol Commun [Internet]*. 2020;4(1):40–2. Available from: <https://doi.org/10.1080/24734306.2020.1757967>

